- Kindeva and Rocket Science Health have signed a non-exclusive agreement to seek partners for the development of a targeted intranasal drug delivery device.
- The partnership combines RSH’s novel technology with Kindeva’s CDMO and regulatory expertise to prepare for clinical trials and commercial readiness.
Kindeva, a global CDMO specialising in drug-device combination products, has announced a collaboration with Canadian health technology company Rocket Science Health (RSH) to support the development of a novel intranasal delivery platform. The agreement aims to identify commercial and development partners for RSH’s Olfactory Delivery Device.
The technology is designed to deliver medication directly to the Olfactory Clefts, a region of the nasal cavity that is typically difficult to reach. Unlike traditional mist-based sprays, the RSH device uses a laminar stream to improve deposition accuracy and features proprietary dispensing tips that bypass the nasal valve. It also incorporates user-centric design to facilitate correct dosing, especially for patients with physical or cognitive impairments.
The collaboration is expected to accelerate the product’s path to clinical trials and, ultimately, regulatory approval. As part of the agreement, Kindeva will provide contract manufacturing and development support, leveraging its established expertise in intranasal drug delivery and commercialisation.
“We are ready to bring this technology into clinical trials,” said Kenneth Irving, Founder and CEO of Rocket Science Health. “Kindeva stood out not only for their track record of supporting drug developers through the trial process, but for their history and shared commitment to making meaningful innovations widely accessible.”
Stay ahead of trends and best practices
